Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient
Pancreatic cancer is the fourth biggest killer, and has one of the worst prognoses, of any cancer type. Approximately 95% of patients diagnosed with pancreatic cancer will not survive beyond 5 years post diagnosis, and these statistics have barely improved in over 40 years. Here, genomic changes in one particular patient with stage IV metastatic pancreatic cancer were explored to suggest a potential personalized treatment. In particular, exome sequencing of genomic DNA extracted from blood and the cancer biopsy was utilized with the aim of identifying mutational drivers of the cancer. This analysis revealed a splice site mutation in RBCK1 as the most promising driver of the cancer and a therapy based on a pan-cyclin-dependent kinase (pan-CDK) inhibitor, flavopiridol. This study suggests that drugs whose effectiveness is unclear for general populations of cancer sufferers should possibly be reconsidered for specific patients where the drug could be rationally argued to improve outcome.
|ISBN||1178-6930 (Electronic) 1178-6930 (Linking)|
|Responsible Garvan Author|
|Publisher Name||OncoTargets and Therapy|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/24833909|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/12334|